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Objective 
To summarize the long-term efficacy and safety of tacrolimus 
in orthotopiC liver transplant (Ol T) recipients, as well as to 
examine the factors that influence long-term morbidity and 
mortality rates. 
Background 
Tacrolimus (FK506, Prograf) was introduced as primary im-
munosuppression for primary liver transplantation in 1989; 
many subsquent trials have verified the association of tacroli-
mus with decreased rates of acute rejection and steroid-resis-
tant rejection after OlT. Cumulative experience with tacroli-
mus has also defined its short- and intermediate-term toxicity. 
Methods 
One thousand consecutive patients undergoing primary Ol T 
at a single center from August 1989 to December 1992, un-
der tacrolimus immunosuppression, were followed until Janu-
ary 1999. Patients were categorized by age. Mean follow-up 
was 93.4 :t 11 months after OlT. Patient survival, graft sur-
vival (with corresponding causes of death and retransplanta-
tion), and rejection rates (and corresponding doses of immu-
nosuppression) were examined as efficacy parameters. 
Hypertension, renal function, incidence of malignancies, inci-
dence of diabetes, and other toxicities were examined as 
safety parameters. 
Results 
Actual 6-year overall patient survival rate was 68.1 % and graft 
survival rate was 62.5%, with significant differences in the 
patterns of survival among the different age groups. After the 
first post-Ol T year, infection, recurrence of disease, de novo 
malignancies, and cardiovascular events were the main 
causes of graft loss and death during the long-term follow-up. 
Graft loss related to either acute or chronic rejection was rare. 
The rate of acute rejection beyond 2 years was approximately 
3% per year, and most were steroid-responsive. Approxi-
mately 70% of the patients were receiving tacrolimus mono-
therapy beyond year 1; at the latest follow-up, 74.2% were 
maintained on tacrolimus alone. In 6.1 % of the survivors, end-
stage renal disease developed during the follow-up period, 
requiring either dialysis or kidney transplantation. Hyperkale-
mia and hypertension was observed in approximately one 
third of the patients. Insulin-dependent diabetes mellitus (in-
cluding patients who had diabetes before the transplant) was 
observed in 14% in year 1 , dropping to 11 % in year 7. In 82 
patients, de novo malignancies developed; in 41 patients, 
Iymphoproliferative disorders developed during the entire fol-
low-up period. 
Conclusions 
long-term patient and graft survival rates are excellent under 
tacrolimus immunosuppression. Pediatric patients have a bet-
ter long-term outcome than adults, in part because of the lim-
ited recurrence of the original disease, which was the most 
common cause of late graft loss (other than patient death, 
most commonly the result of late de novo malignancies and 
cardiovascular events). Graft loss from late rejection was rare. 
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Tacrolimus (FK506. Prograf) is a macrolide antibiotic 
derived from the soil fungus Streptomyces Isukubaensis. It 
has potent in vitro and in vivo immunosuppressive qualities. 
Clinical trials with tacrolimus began at our institution in 
March 1989. initially as rescue treatment for failing liver 
allografts under cyclosporine (CsA).1-5 Subsequently. its 
utility was demonstrated in primary liver transplantation 
(OLT).6-8 One clear early benefit was the reduction in the 
number of episodes and severity of acute rejection. which 
was demonstrated by 1990.7.9.10 In addition. the acute tox-
icity profile of tacrolimus was also delineated in these and 
subsequent reports. 1 1-24 
These observations were subsequently verified in three 
prospective randomized trials. which were conducted before 
FDA approval: the Pittsburgh single-center trial, in which 
tacrolimus was compared with CsA. both using low-dose 
steroids alone;25.26 and the U.S. and European multicenter 
trials comparing tacrolimus with low-dose steroids with 
CsA as part of double. triple. or quadruple induction pro-
tocols.27.28 In these trials. the immediate benefits and limi-
tations of tacrolimus were delineated. Further follow-up of 
the multicenter trials has demonstrated excellent patient and 
graft survival rates. with a long-term toxicity profile that has 
been quite acceptable?9 
The purpose of this study is to evaluate the long-term 
efficacy and side effect profile of tacrolimus in primary 
OLT recipients. using the principal determinants of patient 
survival. graft survival. rates of rejection. baseline immu-
nosuppression. and physiologic abnormalities associated 
with the drug in this population of patients. 
MATERIALS AND METHODS 
The study subjects are the first 1000 consecutive patients 
who received a primary OLT under tacrolimus-based im-
munosuppression between August 1989 and December 
1992. There were 600 male patients and 400 female pa-
tients. with a mean age of 42.6 ± 20.2 years. For purposes 
of this study. infants were defined as ::s; 2 years (n = 75). 
children were > 2 years. ::s; 18 years (n = 91). adults were 
> 18. ::s; 60 years (n = 630). and seniors were> 60 years 
(n = 204). Eight hundred forty-one (84.1 %) patients were 
hospital-bound at the time of OLT. All patients were fol-
lowed until January 1999. The mean follow-up was 93.3 ± 
11 months (range 72-113). The indications for liver trans-
plantation are shown in Table 1. The details of the immu-
nosuppressive protocol used in this group of patients has 
been described before.30.31 However. this group of patients 
represents an earlier experience with tacrolimus. using a 
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Table 1. INDICATIONS 
Postnecrotic Cirrhosis 
Alcoholic cirrhosis 
Biliary atresia 
Primary biliary cirrhosis 
Primary sclerosing cholangitis 
Primary hepatiC malignancy 
Acute fulminant failure 
Miscellaneous 
Total 
n (%) 
341 (34.1) 
188 (18.8) 
86(8.6) 
83(8.3) 
60(6) 
79 (7.9) 
34(3.4) 
129 (12.9) 
1000 (100) 
dosing schedule with higher doses of tacrolimus than are 
used currently.32 
Profiles of rejection. safety parameters. levels of immu-
nosuppression. evidence of disease recurrence. and physio-
logic disturbances were evaluated using a prospective-de-
signed clinical database (Electronic Database Interface for 
Transplantation [EDIT]. Thomas Starzl Transplantation In-
stitute. Pittsburgh. PA). 
RESULTS 
Survival 
The actuarial Kaplan-Meier estimates of patient and graft 
survival are shown in Figures I and 2. The greatest number 
of deaths occurred in the first year; the overall mortality rate 
averaged 3% every year thereafter. with an actual overall 
patient survival rate of 68.1 % and a graft survival rate of 
62.5% at 6 years and a actuarial survival rate at 9 years of 
61.7% (patient) and 56.4% (graft). Of interest is the diver-
gence of survival seen in the 'different age groups. with the 
best long-term survival rate seen in the pediatric group and 
the worst in the elderly. 
The causes of death are shown in Table 2. Overall. 
infectious complications were the most common cause of 
death. particularly in the first year. Thereafter. recurrence of 
disease (including malignancy). de novo malignancies. and 
cardiovascular events constituted the main causes of death. 
As expected. these events were predominantly seen in the 
adult and elderly groups. 
Causes for Retransplantation 
During the entire follow-up period. 170 retransplanta-
tions were performed in the 1000 patients. One hundred 
forty-four patients lost their first graft and underwent a 
second transplant. 22 patients required a third transplant. 
and 4 patients needed a fourth transplant. As shown in Table 
3. primary nonfunction. hepatic artery thrombosis. and re-
currence of disease were the most common reasons for 
retransplantation. As expected. the greatest number of re-
transplantations were performed in the first year (n = 126-
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Figure 1. Kaplan-Meier patient 
survival rates for the 1000 primary 
liver transplant patients. Survival 
figures up to year 6 are actual; 
those after year 6 are actuarial sur-
vivaK 
60 r- -+-Infants (- X -A-........X_ X_ X 
---Children 
40 or-
.... Adults 
20 r- -X-Seniors 
..... Overall 
o 
o 3 12 
74.1 % of total retransplantations); it became a less frequent 
event after that point. In addition, late retransplantations 
were principally for recurrent disease and were mostly 
confined to the adult group. 
Maintenance Immunosuppression 
Tacrolimus 
The mean tacrolimus dose was lower each year after 
OLT, starting at 8.5 mglkg/day at year 1 and dropping to 4.8 
mglkg/day by year 5. Thereafter, doses of tacrolimus tended 
to remain constant. Similarly, the mean plasma tacrolimus 
trough concentration was 0.8 ng/ml at year 1 and 0.7 ng/ml 
at year 4.33 After conversion of the monitoring assay for 
tacrolimus to trough whole blood concentration, the mean 
tacrolimus level was 9.7 ng/ml at year 5 (tacrolimus levels 
<5 ng/ml were considered as 5 ng/ml for purposes of 
calculating levels)34 (Table 4). 
Cyclosporine 
Thirty-seven (4.4%) adults and seniors were converted to 
CsA because of neurologic events (n = 20), lack of appetite 
and failure to thrive (n = 6), hematologic disorders (n = 5), 
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Figure 2. Corresponding Kaplan-
Meier graft survival rates for the 
1000 primary liver allografts. Sur-
vival figures up to year 6 are actual; 
those after year 6 are actuarial sur-
vival. 
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Months Post Transplant 
and other infrequent causes (n = 6). Currently, eight adults 
and seniors (1.6%) are receiving CsA. None of the infants or 
children require CsA, and none of the patients received CsA 
with tacrolimus simultaneously. 
Corticosteroids 
Approximately 70% of the patients were maintained 
without prednisone. Even the patients who required pred-
nisone at I year (13%) were able to take lower doses of 
prednisone in subsequent years. Thus, although 15% of the 
patients were receiving >5 mg/day of prednisone at 1 year, 
this declined to 5% at year 5 (see Table 4). 
Adjunctive Immunosuppressive Agents 
Azathioprine was not used routinely after OLT, and my-
cophenolate mofetil was not available during this period. In 
only selected patients was azathioprine (and since 1995 
mycophenolate mofetil) used, generally to minimize neph-
rotoxicity ascribed to tacrolimus. Currently, 27 adults/se-
niors and 4 infants/children are receiving azathioprine, 
whereas 9 adults/seniors and 5 infants/children are receiving 
mycophenolate mofetil. The azathioprine doses used were 
usually <50 mg/day; no patient received > 100 mg/day. 
Mycophenolate mofetil doses averaged <2 g/day. 
- - - - - - -
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Table 2, CAUSES OF DEATH 
Infection 
Cardiopulmonary 
Recurrent + de novo cancer 
Recurrent disease 
Multisystem organ failure 
Cerebrovascular 
Miscellaneous 
Total 
Adverse Events 
Nephrotoxicity 
n (%) 
123 (34) 
57 (16) 
53 (15) 
43 (12) 
18 (5) 
16 (4) 
50 (14) 
360 (100) 
Nephrotoxicity was the most common complication of 
tacrolimus use. However. after OLT, there was little change 
in the mean serum creatinine level or blood urea nitrogen 
over the follow-up period (Table 5). More than 80% of the 
patients had a serum creatinine level ::52.0 mg/dl. Currently, 
20 patients are surviving with kidney transplants performed 
for end-stage kidney disease, whereas 19 patients are cur-
rently receiving hemodialysis. The greatest incidence of 
kidney failure requiring long-term dialysis or kidney trans-
plantation was seen in the adult and senior groups (n = 36. 
7.2% survivors) compared with three in the infant and 
pediatric groups (2.1 % survivors). 
Hyperkalemia 
As shown in Table 6, approximately 40% of patients in 
the first 3 years had hyperkalemia (defined as K+ >5.0 
requiring treatment). This was observed in approximately 
18% of the study population currently (see Table 6). In all 
the cases it was readily controlled with fludrocortisone. 
Hypertension 
Thirty-five percent of the patients are currently receiving 
antihypertensive medications. In >75% of the patients. this 
hypertension was controlled with a small dose of a single 
Table 3. CAUSES OF 
RETRANSPLANTATION 
Causes of first retransplant 
Primary nonfunction 
HepatiC artery thrombosis 
Recurrent hepatitis 
Acute + chronic rejection 
Biliary complications 
Other 
Total 
II: 144 (14%); III: 22 (2%); IV: 4 (0.4%). 
n (%) 
63(6.3) 
45(4.5) 
11 (1.1) 
11 (1.1) 
8 (0.8) 
6(0.6) 
144 
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Table 4. IMMUNOSUPPRESSION 
Months 
Post-OLT 3 6 12 24 36 48 60 
Tacrolimus dose 11.0 10.5 8.5 6.9 5.9 6.0 4.8 
mg/d' 
Tacrolimus level 1.0 0.9 0.8 0.7 0.6 0.7 9.7t 
ng/ml' 
Prednisone 
o mg/day (%) 53 57 67 72 71 66 67 
1-9 mg/day 37 35 30 24 25 29 28 
(0/0) 
2:10 mg/day 10.0 8.0 3.0 4.0 4.0 5.0 5.0 
(0/0) 
, Mean value. 
t Whole blood trough levels (others are plasma leveQ. 
antihypertensive agent, usually a calcium channel blocker 
(see Table 6). 
New-Onset Diabetes 
Fourteen percent of the patients at year I and 11 % of the 
patients currently are receiving insulin, as shown in Table 6. 
De Novo Malignancies 
In 82 patients, de novo malignancies developed, 33 of 
which were skin cancers, including 2 melanomas. The re-
maining were gastrointestinal (n = 11), genitourinary (n = 
9) pulmonary (n = 8), oropharyngeal (n = 7), breast (n = 
3), leukemia (n = 3), Kaposi sarcoma (n = 2), thyroid (n = 
2), unknown primary (n = 2), brain (n = I), conjunctiva 
(n = 1), and de novo hepatocellular carcinoma (n = 1) 
(Table 7). 
Lymphoproliferative Disorders 
Lymphoproliferative disorders developed in 18 (10.8%) 
children or infants and in 23 (2.8%) adults or seniors. Sites 
are shown in Table 8. 
Technical Complications 
A total of 21 (12.7%) bile duct complications were ob-
served in infants/children and 177 (21.2%) in adults/seniors 
during the entire study. In the pediatric popUlation, these 
consisted of extrahepatic strictures in II, intrahepatic stric-
tures in 8, and bile duct leaks in 2 in the pediatric popula-
Months 
BUN 
Creatinine 
Table 5, NEPHROTOXICITY* 
o 3 6 12 24 36 
22 31 30 29 27 27 
1.1 1.7 1.7 1.7 1.6 1.6 
, Values (mg/dl) determIned in survivors. 
48 
26 
1.7 
60 
25 
1.7 
.... 
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Table 6. PHYSIOLOGIC DERANGEMENTS 
Months 3 6 12 24 36 48 60 Current 
Hypertension (%) 
Diabetes mellitus (%) 
Hyperkalemia (%) 
Chol. (Mean:mg/dl) 
29 
24 
39 
102 
29 31 37 
13 14 15 
44 47 46 
159 165 172 
36 41 46 
16 17 18 
40 38 35 
176 179 178 
35 
11 
18 
179 
tion. In the adult/senior population. they consisted of 1 19 
extrahepatic strictures. 29 intrahepatic strictures. 28 ampul-
lary dysfunctions. and 28 bile leaks. 
Seventy-six patients had hepatic artery complications 
(7.6%)-64 (7.6%) in the adultJsenior group and 12 (7.2%) 
in the pediatric population. These complications consisted 
of thrombosis in 44 patients. strictures in 28. and aneurysms 
in 4. Although most of the arterial complications in infants/ 
children occurred within the first postoperative month. in 
adults/seniors these complications occurred early and late 
after OLT in equal proportions. 
DISCUSSION 
The introduction of CsA led to significant improvements 
in OLT patient survival and graft survival rates, with reduc-
tion in the incidence and severity of rejection.35.36 In addi-
tion. the safety profile of CsA was determined early. with 
nephrotoxicity. hepatotoxicity. and neurotoxicity being par-
ticularly notable.37.38 However. even after a decade of use in 
liver transplantation, many questions still remained.39 
The use of the more potent immunosuppressive agent 
tacrolimus has further reduced the frequency and severity of 
rejection in OLT.25.27.28.32 As demonstrated in randomized 
OLT trials comparing a simplified tacrolimusllow-dose ste-
Table 7. DE NOVO NONLYMPHOID 
MALIGNANCIES· 
Skin 
Melanoma (2) 
Other (31) 
Gastrointestinal 
Genitourinary 
Lung 
Oropharyngeal 
Miscellaneous 
Breast (3) 
Leukemia (3) 
Unknown primary (2) 
Kaposi's (2) 
Thyroid (2) 
Brain (1) 
Eye (1) 
Uver (1) 
• Total: 82 (8.2%) 
t Incidence significantly higher than expected. 
33 
10 
9 
8 
7t 
15 
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Table 8. LYMPHOID MALIGNANCIES 
Adults/Seniors Children/Infants 
Site n (%) n (%) 
Lymph node 10 (43) 6 (33) 
Gastrointestinal 5(22) 5 (28) 
Uver 4 (19) 3 (17) 
Lung 2(9) 2 (11) 
Tonsil 2 (9) 1 (6) 
Skin 0 1 (5) 
Total 23 (2.8) 18 (10.8) 
roid protocol with more complex CsA-based immunosup-
pressive regimens. patient and graft survival rates in the 
tacrolimus groups at 1 year were equal to or better than that 
for CsA, despite the artifact introduced by the high rate of 
successful conversions of CsA patients to tacrolimus for 
treatment of rejection.32 The lower rate of rejection under 
tacrolimus may be in part due to the ability of increasing 
tacrolimus levels to reverse ongoing rejection.2.4O In addi-
tion. other metabolic benefits were seen. such as lowered 
incidence of hypercholesterolemia and hypertriglyceride-
mia.41 This survival difference has been magnified in fol-
low-up reports of patients entered in this trial. and the 
benefits of tacrolimus therapy appear to be sustained at 5 
years after OL T.42 The rate of late acute rejection remains 
low and is often associated with noncompliance. The inci-
dence of chronic rejection also appears less than that re-
ported under historic CsA experiences (Demetris AJ. manu-
script in preparation). 
Both patient and graft survival rates were statistically 
significantly better in the pediatric popUlation (infants and 
children) than in the adult population (adults and seniors).43 
In this analysis. the pediatric popUlation enjoyed an overall 
6-year actual survival rate of >85%. This compares very 
favorably with contemporaneous reports on pediatric trans-
plantation under CsA.44 Most of the diseases likely to recur 
(e.g .• hepatitis C, primary sclerosing cholangitis. and alco-
holic liver disease) are seen in adult men; thus. recurrence of 
disease is likely to lead to diminished long-term patient and 
graft survival rates.45 
In this large series of comprehensively followed OLT 
patients receiving tacrolimus, with the longest follow-up 
available, we sought to profile the factors that affect long-
term morbidity and mortality rates. This is particularly 
important because there have been many concerns about the 
durability of CsA and long-term toxicity, including renal 
failure, development of malignancies. and increased risks of 
cardiovascular complications.46 The patients in this study 
received an initial tacrolimus dose three to five times higher 
than those currently used. although the doses at year 7 are 
similar to maintenance doses for more recently transplanted 
patients.47 These results have been achieved using low-dose 
maintenance corticosteroids. and in nearly 70% of patients 
.... 
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corticosteroids have been weaned entirely. Late-term graft 
loss and death are related to recurrence of disease, such as 
malignancies,48 hepatitis B.4lJ hepatitis c.50 and primary 
sclerosing cholangitis. Other have reported no differences in 
the incidence of recurrent disease with one immunosuppres-
sive agent versus another.51 whereas others have suggested 
differences.52 Recurrent primary biliary cirrhosis and recur-
rent autoimmune hepatitis are generally associated with 
allograft dysfunction but not graft loss.5:1 
Despite the concern of long-term chronic nephrotoxicity. 
end-stage renal disease requiring dialysis or kidney trans-
plantation occurred in approximately 6% of patients in this 
long-term follow-up study. This figure is consistent with the 
findings of comparable early nephrotoxicity after OLT us-
ing either CsA or tacrolimus,27.28.54.55 and longer-term fol-
low_up.42.56 The cumulative increase in the development of 
end-stage renal failure in tacrolimus-treated patients is con-
sistent with other reports in CsA-treated patients. 57 The 
incidence and management of hyperkalemia and hyperten-
sion appear to be stable with long-term follow-up. The 
diabetogenicity of tacrolimus appears to be limited: there 
was no significant difference in the incidence at year I 
(14%) and at year 6 (11%). The lower levels of tacrolimus 
late after OL T may account for a decreased incidence of 
diabetes, as has been shown for other adverse events.58.59 
This study also suggests that cardiovascular risk factors, 
such as hypertension and altered lipid profiles, favor the use 
of tacrolimus, 60 although the increasing use of steroid wean-
ing in CsA-treated patients may improve the profile of these 
cardiovascular risk factors. 61- 64 The cardiovascular risk 
profile of the newer CsA formulation Neoral does not ap-
pear to be much different than the standard formulation in 
OLT patients.65 
The enhanced immunosuppressive potency of tacrolimus 
does not appear to be associated with a late risk for devel-
opment of malignancy. Lymphoproliferative disorders de-
veloped in 41 patients in this series, in which higher doses 
of tacrolimus were initially used: the predominance in the 
pediatric population (12.7%) was significantly higher than 
in adults (2.8%). The risk factors for the higher incidence in 
pediatric patients has been previously reported.66 Fortu-
nately, in both popUlations, the majority (>70%) of patients 
survived with resolution of the Iymphoproliferative disorder 
(data not shown). Finally, the risk of non lymphoid tumors 
does not appear to be higher than for CsA, with a wide 
variety of solid and hematologic malignancies.67 The age-
adjusted risk appears increased for the aerodigestive system 
only.68 We have previously suggested that the increased 
incidence in aerodigestive malignancies may be associated 
with the risk factors of a long smoking history and chronic 
alcohol use. However, de novo malignancies are a risk 
factor for long-term survival in adult and senior OLT recip-
ients, whether the incidence is increased or not, compared 
with age-adjusted general population cohorts.69.7o 
In conclusion, the principal limitations of long-term OLT 
survival no longer include rejection. Recurrent diseases, in 
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particular recurrent malignancy and recurrent viral hepatitis. 
as well as cardiovascular events, are the major causes of 
graft and patient loss. The development of de novo malig-
nancies may be prevented by careful screening, and effec-
tive treatment can be instituted with earlier detection. Long-
term survival in pediatric patients is excellent: the risk of 
lymphoproliferative disease development is higher, but the 
impact on survi val is minimal. 
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Discussion 
DR. DAVID L. DUNN (Minneapolis. Minnesota): I rise to congrat-
ulate Drs. Fung, Stan!. and colleagues for an excellent presenta-
tion providing us with much more than an incremental advance in 
the immunosuppressive drug therapy for transplantation. This is a 
very interesting study, and it follows on the heels of several 
prospective randomized trials comparing other immunosuppres-
sive drugs, particularly cyclosporine, to FK506 or tacrolimus. 
It is an interesting study from an historical perspective because 
the Pittsburgh group very clearly resurrected tacrolimus. The ini-
tial studies with FK506 experimentally and clinically indicated to 
us that it was diabetogenic, that there were problems associated 
with arteritis. Yet they persevered and very clearly have demon-
strated enhanced graft survival. and therefore patient survival, in 
this liver transplant patient population. 
Having said that, I have several questions for you. Dr. Fung. 
First, cyclosporine and FK506 are so similar from an immuno-
logic standpoint. Why is it, do you think, that this is a superior 
drug? Is there something different about the liver immunologically 
that lends itself to FK506 immunosuppressive drug therapy? 
Secondly. it did seem as though initially you observed a slightly 
higher incidence of diabetogenic properties. Have you seen that in 
this trial now showing us long-term results? 
Thirdly, looking at the steroid withdrawal in your patients. was 
this done by protocol in the FK506 patients, and was it similar to 
the previously studied cyclosporine patients? It was not clear to me 
in the manuscript whether this was the case, as certainly that would 
influence your overall allograft and therefore patient survival. 
Lastly, you have once again shown us a relatively high inci-
dence of PTLD in your pediatric liver transplantations. Is that 
similar to your previous studies with cyclosporine or is it different 
with FK506? 
PRESENTER DR. JOHN J. FUNG (Pittsburgh, Pennsylvania): The 
mechanism of action of FK506 and cyclosporine share a common 
pathway of inhibiting calcineurin-mediated activation of T cells. 
However. there may be a biologic difference in the induction of 
drug resistance by these two agents. 
One hypothesis has been that p-glycoprotein. which is respon-
sible for modulating cellular efflux of both cyclosporine and ta-
crolimus, is differentially induced by these agents. Tacrolimus 
appears to be associated with decreased induction of this pathway 
of drug resistance. Outside of this mechanism, and pharmacoki-
netic differences between these agents, there isn't a clear expla-
nation. There has also been some speculation that TGF-f3 expres-
sion is enhanced with tacrolimus. which may account for some 
immunosuppressive benefit. 
In addressing some of the adverse events associated with ta-
crolimus, particularly diabetes, there was an early learning curve. 
Currently, we are using tacrolimus doses that are between 50% and 
75% lower than was used during the period in question. Having 
said that. I do believe that tacrolimus alone does have a diabeto-
genic potential, but not substantially greater than cyclosporine/ 
corticosteroids. 
Recently, patients who develop complications, such as nephro-
toxicity and diabetes, will be converted to a triple drug regimen 
with mycophenolate. And Ron Shapiro's data from our kidney 
transplant group shows a significant reduction of diabetes with 
tacrolimus steroids and mycophenolate. Thus, the polypharmacy 
approach can be of benefit to a certain group of patients. 
This study demonstrated to us that steroid weaning could be 
achieved easily, and altered our approach to management of pa-
tients on both tacrolimus and cyclosporine. I feel that most of our 
clinicians are more willing to wean steroids in all transplant 
patients. This was not a comparative study. However, both the 
American and European multicenter tacrolimus and cyclosporine 
trials did show a benefit of tacrolimus in terms of lowering base-
line corticosteroid requirements. 
Lastly, the incidence of PTLD with the use of tacrolimus is 
within the range that has been previously described with cyclo-
sporine. But I think one of the things that has been different is that 
our understanding of PTLD-what we consider PTLD is-con-
tinues to evolve. We are currently now using quantitative EBV-
PCR to detect EBV and have introduced both with the introductive 
preemptive ganciclovir therapy. These modifications appear to 
have diminished the frequency and severity of PTLD. 
DR. DONALD C. DAFOE (Palo Alto, California): Dr. Fung, this is 
an impressive experience. A thousand procedures of any sort is a 
remarkable accomplishment: 1000 liver transplants, truly awe-
inspiring. Through all-inclusive long-term reports like this one 
where all the data are laid out, the Pittsburgh group, Drs. Stanl, 
Fung. and colleagues, continue to establish the benchmarks for 
other programs. 
It is clear that tacrolimus monotherapy provides excellent pa-
tient and graft survival. But the downside of tacrolimus and any 
other effective regimen is infection, oncogenicity. recurrent dis-
ease, hypertension, diabetes. and accelerated cardiovascular dis-
ease. I suspect this paper sets the stage for the next phase at 
Pittsburgh of tolerance induction through the establishment of 
stable chimerism. as suggested by the paper we heard yesterday 
from Dr. Corry. Until that day arrives, I have a few questions. 
Due to the incidence of diabetes and other tacrolimus-related 
problems, should the dose be lower and should other agents such 
as mycophenolate be added back? 
Although some of the causes of graft and patient loss such as 
cancer can be addressed through vigilant follow-up. recurrent 
c 
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hepatitis is less amenable to early diagnosis and treatment. I would 
like to ask whether lamivudine has had an Impact on your recurrent 
hepatitis B. And given the impending epidemic of hepatitis C 
leading to end-stage liver disease. what is your current strategy to 
prevent recurrent hepatitis C' 
DR. FUNG: All of us who deal with liver transplantation are 
concerned with recurrent disease. particularly hepatitis C. 
We know that almost 100Cif- of patients that are transplanted for 
hepatitis C have recurrent infection. although the timing and inci-
dence of developing complications of this recurrent disease are 
quite variable. Unfortunately. we have seen patients that have had 
recurrent hepatitis C destroy their livers within a short period of 
time. 6 months. Unfortunately. the treatment that is available is 
very limited. Ribavirin and interferon protocols at best clear virus 
in about 5 to 10% of patients. So we would say that this represents 
a dismal outlook. 
There is a definite trend toward using lower-dose tacrolimus 
with a lower threshold to adding other agents like mycophenolate. 
We completed a tacrolimus and steroid versus tacrolimus. steroid. 
and mycophenolate randomized trial. Dr. Jain reported this at the 
ASTS last year. There is a clear decreased incidence of nephro-
toxicity and diabetogenicity. 
It will be of interest to determine a variety of new immunosup-
pressive agents. e.g .• IL-2 receptor monoclonals and rapamycin in 
future trials. 
DR. MARLON LEVY (Dallas. Texas): Dr. Fung. thank you for 
making your manuscript available for review. I also congratulate 
you on spectacular results. Really. no one in the transplant world 
can match Pittsburgh's numbers and longevity and the ability to 
report series such as these. I think both your paper and your 
presentation were interesting and odd in a way. There is sort of a 
shadow-boxing going on with comparing cyclosporine. and yet 
you don't really ever give any data on cyclosporine. So it is sort of 
an odd way to present this. 
My questions are related to specific immunosuppressive strate-
gies. You cite an extremely low incidence of chronic rejection. 
extremely low incidence of graft loss due to chronic rejection. but 
all except one of the primary advantages of FK is its ability to 
modulate both the key rejection and chronic rejection. So what is 
your strategy for chronic rejection, specifically as it relates to FK. 
and what is your incidence of chronic rejection? 
The second question is about how you are now integrating 
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Progruf with some of the newer immunosuppressants. You have 
talked a little bit about CellCept. What about perhaps rapamycin 
and some of the new generation monoclonals. including either the 
humanized or the chimeric monoclonals? 
DR. FLING: Baylor was a key institution in the multicenter 
tacrolimus trial in liver transplantation and appreciated some the 
problems with the early learning phase. We have not had the 
opportunity of using any of the anti-IL-2 receptor monoclonal 
antibody preparations. 
The NIDDK study clearly showed that acute rejection per se 
does not necessarily portend a poor outcome in liver transplant. So 
the prevention of acute early rejection in livers doesn't have the 
same kind of impact that has been reported in kidney transplanta-
tion. We have not tried to further reduce acute rejection episodes. 
which under tacrolimus and mycophenolate are running about 
20%. I think a zero incidence of rejection would increase the risk 
of infection. as Dr. Diethelm had suggested. 
I think there should be better individualization of patients for 
immunosuppressive agents and more thoughtfulness given to 
agents that are selected. For example. somebody with alcoholic 
liver disease doesn't have the same risk of rejection as. say. 
someone with autoimmune hepatitis. This patient might benefit 
from less immunosuppression. 
With de nol'O malignancy. particularly the aerodigestive tract. 
malignancies were seen predominantly in the alcoholic group. 
These patients have risk factors for aerodigestive cancers based on 
their smoking and drinking history. Once we identified this as 
being a risk in this particular group. we increased our screening. so 
all of our patients that had a history of smoking are subjected to 
very careful ENT examination. We have picked up a number of 
severe dysplasias and vocal cord and laryngeal malignancies. 
These types of high-risk patients may be better off on rapamycin. 
since rapamycin has antiproliferative potential in malignancies. 
Lastly. this was not a study that was designed to compare 
tacrolimus with cyclosporine. As you know. this data was being 
accumulated during the period the U.S. and European multicenter 
trials were being conducted. This single-center experience allowed 
us to get a very good handle on limitations ofFK. Since Dr. Todo's 
initial presentation at this meeting 6 years ago. we much better 
understand the side-effect profile. As this experience has evolved. 
we have been able to maximize the benefits of tacrolimus while 
minimizing its toxicities. 
